Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20442236 | 0.97 | FAAH (0.40) | FAAHNR1I2TDP1L3MBTL1LMNA | |
| SCHEMBL21661962 | 0.97 | FAAH (0.40) | FAAHNR1I2TDP1L3MBTL1LMNA | |
| SCHEMBL22308327 | 0.95 | FAAH (0.40) | FAAHNR1I2TDP1L3MBTL1LMNA | |
| SCHEMBL25726630 | 0.93 | FAAH (0.35) | FAAHTDP1L3MBTL1KCNH2 | |
| SCHEMBL21360381 | 0.90 | NR1I2 (0.40) | FAAHNR1I2TDP1L3MBTL1LMNA | |
| SCHEMBL26538816 | 0.90 | KCNA5 (0.33) | FAAHKCNH2 | |
| SCHEMBL26666923 | 0.83 | KCNA5 (0.32) | FAAHKCNH2 | |
| SCHEMBL19308338 | 0.82 | FAAH (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL30664064 | 0.82 | FAAH (0.40) | FAAHTDP1L3MBTL1LMNAKCNH2 | |
| SCHEMBL22647103 | 0.80 | FAAH (0.38) | FAAHTDP1L3MBTL1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | FAAH 564/4885NR1I2 253/4885TDP1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.